GLP-1 maintenance phase: what the science says vs. TikTok

What did @mariahhopkins_ actually say?

She described an 18-month GLP-1 maintenance protocol starting with semaglutide at 0.25 mg, climbing to 1.25 mg, hitting her weight goal around month four, then tapering down by 0.25 mg increments weekly. Once she bottomed out at 0.25 mg every 14 days, she held there for a year before switching to tirzepatide at 2.5 mg weekly.

She also said, "maintenance is so incredibly important whether you do it for one month or two months or forever," and acknowledged that "sometimes your doctor's just trying to figure out with you" what the right approach looks like. That last part is refreshingly honest, and worth remembering.

She is not positioning herself as a clinician. She is sharing a personal experience and explicitly inviting others to weigh it against what works for them. That framing matters when evaluating what she said.

Does the science back this up?

Partially. The general idea that a slow taper can help maintain weight loss is supported by data, but the specific weekly decrement schedule she describes has no standardized clinical backing. Most published evidence focuses on abrupt discontinuation versus continuation, not structured titration-down protocols.

The STEP 4 trial (Rubino et al., 2021, JAMA) is the clearest reference point here. Participants who discontinued semaglutide after 20 weeks regained roughly two-thirds of their lost weight within a year. The trial did not test tapering. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar rebound dynamics with tirzepatide discontinuation. Neither study evaluated a patient-designed maintenance taper like the one described.

Her tirzepatide switch at 2.5 mg weekly is the FDA-approved starting dose for Zepbound and Mounjaro. Staying at that floor dose for maintenance is plausible, but there is no published trial specifically comparing 2.5 mg maintenance against higher doses or against semaglutide extended-interval dosing for long-term weight stability.

What did they get wrong (or right)?

She got the spirit of maintenance right. Weight regain after GLP-1 discontinuation is real and well-documented, and her instinct to stay on a low dose rather than stop entirely is consistent with what the evidence suggests. Credit where it is due.

What is less defensible is the specific taper schedule. Dropping 0.25 mg per week, then stretching to every 10 days and then 14 days, is a self-designed protocol with no peer-reviewed support. It may have worked for her. That does not make it a generalizable approach.

She also said she switched to tirzepatide "just because I wanted to try it, there was really no reason." Clinically, semaglutide and tirzepatide have meaningfully different mechanisms. Tirzepatide is a dual GIP/GLP-1 agonist, not a direct substitute. Treating the switch as interchangeable or casual undersells a real pharmacological difference that patients and prescribers should discuss explicitly.

• Strength: Promotes staying on GLP-1 therapy during maintenance rather than stopping cold.
• Weakness: Presents a self-designed taper schedule as a working framework without clinical sourcing.
• Weakness: Treats a semaglutide-to-tirzepatide switch as low-stakes when mechanism differences exist.

What should you actually know?

GLP-1 maintenance is genuinely under-studied. Most trials are designed to show weight loss efficacy, not to answer what happens when you try to wean down over months. That gap means patients and doctors are often working from limited evidence, which is exactly what she acknowledged.

The published data that does exist points in one direction: stopping GLP-1 therapy tends to result in weight regain. A 2022 analysis by Wilding et al. in Diabetes, Obesity and Metabolism found that the physiological drivers of obesity persist after drug discontinuation, which is why maintenance strategies matter at all.

If you are considering a maintenance plan, the honest answer is that there is no universally validated protocol. Some clinicians extend dosing intervals, some hold at a minimum effective dose, and some cycle patients off with close monitoring. All of those approaches are being used in real practice without strong head-to-head trial data to rank them.

What this video should not be is a dosing blueprint. Her schedule worked for her, in her body, under her prescriber's supervision. Copying it without your own provider involved is not a logical extension of that experience.